AU · rank #20 · 2026-09-10
DSFIR
AMSTERDAM · EUR · $26.04B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.619 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.04 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 13 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $93.62 | +2.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +18.94% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.2% |
| 52w high | $96.74 |
| Market cap (USD) | $26.04B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich AG is a global specialty chemicals leader producing nutritional, sensorial, and beauty ingredients for food, pharmaceutical, and personal care markets, currently focusing on high-margin human health segments [2, 3].
Rationale
The model's strong upward revision signals and 100% revision agreement are fundamentally supported by a Q2 2026 earnings beat, 6% like-for-like sales acceleration, and the margin-accretive €2.2 billion divestment of its animal nutrition business [1, 5].
Material risks
- 1Commoditization of the company's legacy vitamin and nutritional ingredient portfolios by lower-cost rivals, which could erode pricing power and offset specialty division growth [4, 6].
- 2Failure to realize the targeted €300–350 million in sales synergies or execute the transition needed to meet ambitious 21-23% mid-term adjusted EBITDA margin targets [5, 6].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.